Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Santhera Pharmaceuticals Holding AG

< Previous 1 2 Next >
Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® (Vamorolone) in Russia
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Provides Update on Convertible Bond Issued on 23 September 2025
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera extends Highbridge convertible bond to 30th September 2025
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Full Year Results for the Year Ended 31 December 2024
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Publishes Agenda for its Annual General Meeting
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera shares updates on commercial rollout of AGAMREE®
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera proposes Dr. Melanie Rolli as new member of Board of Directors
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Full Year Trading Update
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in Germany
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Chief Financial Officer Transition with Appointment of Catherine Isted
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in Qatar
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Positive Topline Results from LIONHEART Study with AGAMREE® (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback